Research and Markets (http://www.researchandmarkets.com/research/d26e3f25/estonia_pharmaceut) has announced the addition of the "Estonia Pharmaceuticals and Healthcare Report Q2 2012" report to their offering.
Business Monitor International's Estonia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Estonia's pharmaceuticals and healthcare industry.
BMI View: Estonia's pharmaceutical market will remain of marginal interest to multinationals given its small population and a modest growth outlook. The market is expected to post a five-year compound annual growth rate (CAGR) of 5.07% in local currency terms through to 2016, with the following five years likely to have similar annual growth rates. Nevertheless, Estonia's proximity to Western Europe will ensure the market continues to be supplied by leading foreign players.
Key Trends And Developments:
- The Estonian government will provide subsidised discounts on about 30 new drugs in early 2012. It decided to give a 50-100% discount on prescription medicines for treatment of infertility, rheumatoid arthritis, schizophrenia and other conditions, the Ministry of Social Affairs said. According to a legislative amendment, doctors must write prescriptions on the basis on the active ingredient, while the pharmacist is required to recommend the cheapest drug as the first option to patients.
Key Topics Covered:
- Executive Summary
- SWOT Analysis
- Pharmaceutical Risk/Reward Ratings
- Estonia - Market Summary
- Industry Developments
- Industry Forecast Scenario
- Competitive Landscape
- Company Profiles
- Country Snapshot: Estonia Demographic Data
- Glossary
- BMI Methodology
- Sources
Companies Mentioned
- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
- Sanofi
- Merck & Co
- Grindeks (incorporating Tallinn Pharmaceutical Plant)
For more information, including full table of contents, please visit http://www.researchandmarkets.com/research/d26e3f25/estonia_pharmaceut